Presentations
AAN 2022 Poster - Pharmacokinetics, Pharmacodynamics, and Safety of the Highly Selective Dopamine D1/D5 Agonist Tavapadon: Summary of Early Phase Clinical Studies
Apr 05, 2022
AAN 2022 Poster - Levodopa and Dopamine Agonist Medication Utilization among Patients with Parkinson’s Disease Enrolled in Commercial and Medicare Advantage Part D Health Plans
Apr 05, 2022
AAN 2022 Presentation - Darigabat: pronounced antiepileptic activity in the mesial temporal lobe mouse model of drug-resistant focal epilepsy
Apr 05, 2022
AAN 2022 Poster - Ensuring the Continuity of Data Collection in a Focal Epilepsy Clinical Trial During the COVID-19 Pandemic
Apr 05, 2022
4Q 2021 Financial Results & Business Update
Mar 01, 2022
Topline Results for Darigabat in Phase 1 Acute Anxiety Clinical Trial Presentation
Feb 15, 2022
J.P. Morgan Healthcare Conference Presentation
Jan 10, 2022
Evaluation of M4 Muscarinic Receptor Occupancy by CVL-231 in Nonhuman Primates
Dec 08, 2021
CVL-231: Results From an Early Proof-Of-Concept Study in Patients With Schizophrenia
Dec 08, 2021
Cerevel Therapeutics Corporate Presentation
Nov 10, 2021